CV Sciences granted patent in Japan for potential treatment of smokeless tobacco addiction that combines CBD and nicotine

Photo © Shutterstock.com/jovan vitanovski

CV Sciences Inc. (San Diego, CA) has received a formal Certificate of Grant from the Japanese Patent Office (JPO) for its patent application 7216697, which covers methods for the treatment of smokeless tobacco addiction through the administration of pharmaceutical formulations containing cannabidiol (CBD) and nicotine. Corresponding patents applications for similar patent protection were also files in other key markets, with granted patents in the United States, Canada, Australia, Germany, Great Britain, France, Spain, Netherlands, and Italy.

“The worldwide market for smokeless tobacco addiction is a multi-billion dollar sector, providing a life-changing treatment to people around the world,” said Joseph Dowling, CEO of CV Sciences, in a press release. “CV Sciences’ developmental efforts surrounding CBD and nicotine have the potential to alter healthcare with a safe, natural method to reducing addiction to harmful substances. JPO’s patent grant further validates our first-of-its-kind treatment and positions the company to meet the medical needs of millions of patients globally.”

The JPO formal grant will further the development efforts of the drug candidate CV Sciences seeks approval with the U.S. Food and Drug Administration (FDA). If approved, this product would be the only FDA-approved treatment for smokeless tobacco addiction, say CV Sciences.